Sensus Healthcare, Inc. Common Stock SRTS
i
Market dataready · fetched 2026-11-06T14:33:42.633Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-06T14:32:50.269712718Z
FundamentalsSEC EDGAR · ready · as of 2026-06-30 · fetched 2026-11-06T14:33:41.813906+00:00
Sensus Healthcare, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 2.07 | 456.4% | 46.9% | |||
| 25Δ | 2.30 | 405.4% | 40.0% | |||
| 30Δ | 2.53 | 354.3% | 33.2% | |||
| 35Δ | 5.47 | 389.1% | 95.1% | 2.75 | 303.3% | 26.4% |
| 40Δ | 4.23 | 303.9% | 53.7% | 2.98 | 252.2% | 19.6% |
| 45Δ | 3.83 | 297.3% | 42.7% | 3.18 | 245.1% | 17.1% |
| 50Δ | 3.60 | 311.2% | 38.4% | 3.38 | 241.9% | 14.9% |
| 55Δ | 3.38 | 325.2% | 34.1% | 3.58 | 238.7% | 12.7% |
| 60Δ | 3.15 | 339.2% | 29.8% | 3.78 | 235.4% | 10.6% |
| 65Δ | 2.92 | 345.5% | 25.3% | 3.98 | 232.2% | 8.4% |
| 70Δ | 2.67 | 336.5% | 20.5% | 4.44 | 247.9% | 7.1% |
| 75Δ | 2.42 | 327.5% | 15.6% | 4.93 | 265.5% | 5.9% |
| 80Δ | 2.16 | 318.4% | 10.8% | 5.30 | 257.6% | 4.4% |
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 2.07
- IV
- 456.4%
- B/E move
- 46.9%
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 2.30
- IV
- 405.4%
- B/E move
- 40.0%
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 2.53
- IV
- 354.3%
- B/E move
- 33.2%
35Δ
- Pseudo strike
- 5.47
- IV
- 389.1%
- B/E move
- 95.1%
- Pseudo strike
- 2.75
- IV
- 303.3%
- B/E move
- 26.4%
40Δ
- Pseudo strike
- 4.23
- IV
- 303.9%
- B/E move
- 53.7%
- Pseudo strike
- 2.98
- IV
- 252.2%
- B/E move
- 19.6%
45Δ
- Pseudo strike
- 3.83
- IV
- 297.3%
- B/E move
- 42.7%
- Pseudo strike
- 3.18
- IV
- 245.1%
- B/E move
- 17.1%
50Δ
- Pseudo strike
- 3.60
- IV
- 311.2%
- B/E move
- 38.4%
- Pseudo strike
- 3.38
- IV
- 241.9%
- B/E move
- 14.9%
55Δ
- Pseudo strike
- 3.38
- IV
- 325.2%
- B/E move
- 34.1%
- Pseudo strike
- 3.58
- IV
- 238.7%
- B/E move
- 12.7%
60Δ
- Pseudo strike
- 3.15
- IV
- 339.2%
- B/E move
- 29.8%
- Pseudo strike
- 3.78
- IV
- 235.4%
- B/E move
- 10.6%
65Δ
- Pseudo strike
- 2.92
- IV
- 345.5%
- B/E move
- 25.3%
- Pseudo strike
- 3.98
- IV
- 232.2%
- B/E move
- 8.4%
70Δ
- Pseudo strike
- 2.67
- IV
- 336.5%
- B/E move
- 20.5%
- Pseudo strike
- 4.44
- IV
- 247.9%
- B/E move
- 7.1%
75Δ
- Pseudo strike
- 2.42
- IV
- 327.5%
- B/E move
- 15.6%
- Pseudo strike
- 4.93
- IV
- 265.5%
- B/E move
- 5.9%
80Δ
- Pseudo strike
- 2.16
- IV
- 318.4%
- B/E move
- 10.8%
- Pseudo strike
- 5.30
- IV
- 257.6%
- B/E move
- 4.4%
Options history
Table
| Date | IV (%) |
|---|---|
| 182.98% | |
| 210.48% | |
| 103.73% | |
| 152.27% | |
| 188.71% |
Medical Devices
STE
Steris Corporation is an American Irish-domiciled medical equipment company specializing in sterilization and surgical products for the US healthcare system.
More →STIM
Neuronetics, Inc., a commercial-stage medical technology company, designs, develops, and markets products for patients with psychiatric disorders in the United States and…
More →SYK
Stryker Corporation is an American multinational medical technologies corporation based in Kalamazoo, Michigan. Stryker's products include implants used in joint replacement and…
More →TCMD
Tactile Systems Technology, Inc., a medical technology company, is dedicated to the development and supply of medical devices for chronic diseases in the United States. The…
More →TLSI
TriSalus Life Sciences Inc. (TLSI) is an innovative biopharmaceutical firm at the forefront of enhancing cancer therapy through its proprietary localized drug delivery systems,…
More →TMCI
Description unavailable
More →